De Burlo Group’s Ligand Pharmaceuticals LGND Stock Holding History

De Burlo Group’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-31,900	Closed	-$5.46M	–	102
2018 Q3	$5.46M	Buy	31,900 +4,970	+18%	+$749K	1.02%	36
2018 Q2	$3.48M	Buy	+26,930	New	+$3.01M	0.74%	33

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return

De Burlo Group's LGND Position: Q4 2018 in Review

De Burlo Group sold out of Ligand Pharmaceuticals (LGND) in Q4 2018, closing a stake of 31,900 shares — an estimated $5.46M sold.

De Burlo Group first reported a position in LGND in Q2 2018 and held it in 2 quarters. The position peaked at $5.46M in Q3 2018. 362 funds tracked by Wall St. Rank hold LGND as of Q4 2018.

De Burlo Group reported no remaining Ligand Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
De Burlo Group sold 31,900 Ligand Pharmaceuticals shares in Q4 2018, an estimated $5.46M.
De Burlo Group first reported a position in Ligand Pharmaceuticals in Q2 2018 and held it in 2 quarters.
De Burlo Group's Ligand Pharmaceuticals position peaked at $5.46M in Q3 2018.
362 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2018.

Based on De Burlo Group's 13F filing for Q4 2018, filed 7 Feb 2019.